Global Infant and Child Multiple Vaccine Market Growth 2026-2032
The global Infant and Child Multiple Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
The process of upgrading global multi-vaccine products is a process of solidifying the competitive landscape.
LP Information, Inc. (LPI) ' newest research report, the “Infant and Child Multiple Vaccine Industry Forecast” looks at past sales and reviews total world Infant and Child Multiple Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Infant and Child Multiple Vaccine sales for 2026 through 2032. With Infant and Child Multiple Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Infant and Child Multiple Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Infant and Child Multiple Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Infant and Child Multiple Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Infant and Child Multiple Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Infant and Child Multiple Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Infant and Child Multiple Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Infant and Child Multiple Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
The process of upgrading global multi-vaccine products is a process of solidifying the competitive landscape.
LP Information, Inc. (LPI) ' newest research report, the “Infant and Child Multiple Vaccine Industry Forecast” looks at past sales and reviews total world Infant and Child Multiple Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Infant and Child Multiple Vaccine sales for 2026 through 2032. With Infant and Child Multiple Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Infant and Child Multiple Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Infant and Child Multiple Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Infant and Child Multiple Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Infant and Child Multiple Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Infant and Child Multiple Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Infant and Child Multiple Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Infant and Child Multiple Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Pentavalent Vaccine
- Quadruple Vaccine
- Triple Vaccine
- Others
- 12 Months Below
- 12 Months Above
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sanofi
- GSK
- Mitsubishi Tanabe Pharma
- KM Biologics
- Wuhan Institute of Biological Products
- Walvax Biotechnology
- Chengdu Institute of Biological Products
- Minhai Biotechnology
- What is the 10-year outlook for the global Infant and Child Multiple Vaccine market?
- What factors are driving Infant and Child Multiple Vaccine market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Infant and Child Multiple Vaccine market opportunities vary by end market size?
- How does Infant and Child Multiple Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Infant and Child Multiple Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Infant and Child Multiple Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Infant and Child Multiple Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Infant and Child Multiple Vaccine Segment by Type
2.2.1 Pentavalent Vaccine
2.2.2 Quadruple Vaccine
2.2.3 Triple Vaccine
2.2.4 Others
2.2.5 Infant and Child Multiple Vaccine Sales by Type
2.2.5.1 Global Infant and Child Multiple Vaccine Sales Market Share by Type (2021-2026)
2.2.5.2 Global Infant and Child Multiple Vaccine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Infant and Child Multiple Vaccine Sale Price by Type (2021-2026)
2.3 Infant and Child Multiple Vaccine Segment by Application
2.3.1 12 Months Below
2.3.2 12 Months Above
2.3.3 Infant and Child Multiple Vaccine Sales by Application
2.3.3.1 Global Infant and Child Multiple Vaccine Sale Market Share by Application (2021-2026)
2.3.3.2 Global Infant and Child Multiple Vaccine Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Infant and Child Multiple Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Infant and Child Multiple Vaccine Breakdown Data by Company
3.1.1 Global Infant and Child Multiple Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Infant and Child Multiple Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Infant and Child Multiple Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Infant and Child Multiple Vaccine Revenue by Company (2021-2026)
3.2.2 Global Infant and Child Multiple Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Infant and Child Multiple Vaccine Sale Price by Company
3.4 Key Manufacturers Infant and Child Multiple Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Infant and Child Multiple Vaccine Product Location Distribution
3.4.2 Players Infant and Child Multiple Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR INFANT AND CHILD MULTIPLE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Infant and Child Multiple Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Infant and Child Multiple Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Infant and Child Multiple Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Infant and Child Multiple Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Infant and Child Multiple Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Infant and Child Multiple Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Infant and Child Multiple Vaccine Sales Growth
4.4 APAC Infant and Child Multiple Vaccine Sales Growth
4.5 Europe Infant and Child Multiple Vaccine Sales Growth
4.6 Middle East & Africa Infant and Child Multiple Vaccine Sales Growth
5 AMERICAS
5.1 Americas Infant and Child Multiple Vaccine Sales by Country
5.1.1 Americas Infant and Child Multiple Vaccine Sales by Country (2021-2026)
5.1.2 Americas Infant and Child Multiple Vaccine Revenue by Country (2021-2026)
5.2 Americas Infant and Child Multiple Vaccine Sales by Type (2021-2026)
5.3 Americas Infant and Child Multiple Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Infant and Child Multiple Vaccine Sales by Region
6.1.1 APAC Infant and Child Multiple Vaccine Sales by Region (2021-2026)
6.1.2 APAC Infant and Child Multiple Vaccine Revenue by Region (2021-2026)
6.2 APAC Infant and Child Multiple Vaccine Sales by Type (2021-2026)
6.3 APAC Infant and Child Multiple Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Infant and Child Multiple Vaccine by Country
7.1.1 Europe Infant and Child Multiple Vaccine Sales by Country (2021-2026)
7.1.2 Europe Infant and Child Multiple Vaccine Revenue by Country (2021-2026)
7.2 Europe Infant and Child Multiple Vaccine Sales by Type (2021-2026)
7.3 Europe Infant and Child Multiple Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Infant and Child Multiple Vaccine by Country
8.1.1 Middle East & Africa Infant and Child Multiple Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Infant and Child Multiple Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Infant and Child Multiple Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Infant and Child Multiple Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Infant and Child Multiple Vaccine
10.3 Manufacturing Process Analysis of Infant and Child Multiple Vaccine
10.4 Industry Chain Structure of Infant and Child Multiple Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Infant and Child Multiple Vaccine Distributors
11.3 Infant and Child Multiple Vaccine Customer
12 WORLD FORECAST REVIEW FOR INFANT AND CHILD MULTIPLE VACCINE BY GEOGRAPHIC REGION
12.1 Global Infant and Child Multiple Vaccine Market Size Forecast by Region
12.1.1 Global Infant and Child Multiple Vaccine Forecast by Region (2027-2032)
12.1.2 Global Infant and Child Multiple Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Infant and Child Multiple Vaccine Forecast by Type (2027-2032)
12.7 Global Infant and Child Multiple Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.1.3 Sanofi Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.2.3 GSK Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Mitsubishi Tanabe Pharma
13.3.1 Mitsubishi Tanabe Pharma Company Information
13.3.2 Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.3.3 Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Mitsubishi Tanabe Pharma Main Business Overview
13.3.5 Mitsubishi Tanabe Pharma Latest Developments
13.4 KM Biologics
13.4.1 KM Biologics Company Information
13.4.2 KM Biologics Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.4.3 KM Biologics Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 KM Biologics Main Business Overview
13.4.5 KM Biologics Latest Developments
13.5 Wuhan Institute of Biological Products
13.5.1 Wuhan Institute of Biological Products Company Information
13.5.2 Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.5.3 Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Wuhan Institute of Biological Products Main Business Overview
13.5.5 Wuhan Institute of Biological Products Latest Developments
13.6 Walvax Biotechnology
13.6.1 Walvax Biotechnology Company Information
13.6.2 Walvax Biotechnology Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.6.3 Walvax Biotechnology Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Walvax Biotechnology Main Business Overview
13.6.5 Walvax Biotechnology Latest Developments
13.7 Chengdu Institute of Biological Products
13.7.1 Chengdu Institute of Biological Products Company Information
13.7.2 Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.7.3 Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Chengdu Institute of Biological Products Main Business Overview
13.7.5 Chengdu Institute of Biological Products Latest Developments
13.8 Minhai Biotechnology
13.8.1 Minhai Biotechnology Company Information
13.8.2 Minhai Biotechnology Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.8.3 Minhai Biotechnology Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Minhai Biotechnology Main Business Overview
13.8.5 Minhai Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Infant and Child Multiple Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Infant and Child Multiple Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Infant and Child Multiple Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Infant and Child Multiple Vaccine Segment by Type
2.2.1 Pentavalent Vaccine
2.2.2 Quadruple Vaccine
2.2.3 Triple Vaccine
2.2.4 Others
2.2.5 Infant and Child Multiple Vaccine Sales by Type
2.2.5.1 Global Infant and Child Multiple Vaccine Sales Market Share by Type (2021-2026)
2.2.5.2 Global Infant and Child Multiple Vaccine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Infant and Child Multiple Vaccine Sale Price by Type (2021-2026)
2.3 Infant and Child Multiple Vaccine Segment by Application
2.3.1 12 Months Below
2.3.2 12 Months Above
2.3.3 Infant and Child Multiple Vaccine Sales by Application
2.3.3.1 Global Infant and Child Multiple Vaccine Sale Market Share by Application (2021-2026)
2.3.3.2 Global Infant and Child Multiple Vaccine Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Infant and Child Multiple Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Infant and Child Multiple Vaccine Breakdown Data by Company
3.1.1 Global Infant and Child Multiple Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Infant and Child Multiple Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Infant and Child Multiple Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Infant and Child Multiple Vaccine Revenue by Company (2021-2026)
3.2.2 Global Infant and Child Multiple Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Infant and Child Multiple Vaccine Sale Price by Company
3.4 Key Manufacturers Infant and Child Multiple Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Infant and Child Multiple Vaccine Product Location Distribution
3.4.2 Players Infant and Child Multiple Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR INFANT AND CHILD MULTIPLE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Infant and Child Multiple Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Infant and Child Multiple Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Infant and Child Multiple Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Infant and Child Multiple Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Infant and Child Multiple Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Infant and Child Multiple Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Infant and Child Multiple Vaccine Sales Growth
4.4 APAC Infant and Child Multiple Vaccine Sales Growth
4.5 Europe Infant and Child Multiple Vaccine Sales Growth
4.6 Middle East & Africa Infant and Child Multiple Vaccine Sales Growth
5 AMERICAS
5.1 Americas Infant and Child Multiple Vaccine Sales by Country
5.1.1 Americas Infant and Child Multiple Vaccine Sales by Country (2021-2026)
5.1.2 Americas Infant and Child Multiple Vaccine Revenue by Country (2021-2026)
5.2 Americas Infant and Child Multiple Vaccine Sales by Type (2021-2026)
5.3 Americas Infant and Child Multiple Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Infant and Child Multiple Vaccine Sales by Region
6.1.1 APAC Infant and Child Multiple Vaccine Sales by Region (2021-2026)
6.1.2 APAC Infant and Child Multiple Vaccine Revenue by Region (2021-2026)
6.2 APAC Infant and Child Multiple Vaccine Sales by Type (2021-2026)
6.3 APAC Infant and Child Multiple Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Infant and Child Multiple Vaccine by Country
7.1.1 Europe Infant and Child Multiple Vaccine Sales by Country (2021-2026)
7.1.2 Europe Infant and Child Multiple Vaccine Revenue by Country (2021-2026)
7.2 Europe Infant and Child Multiple Vaccine Sales by Type (2021-2026)
7.3 Europe Infant and Child Multiple Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Infant and Child Multiple Vaccine by Country
8.1.1 Middle East & Africa Infant and Child Multiple Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Infant and Child Multiple Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Infant and Child Multiple Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Infant and Child Multiple Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Infant and Child Multiple Vaccine
10.3 Manufacturing Process Analysis of Infant and Child Multiple Vaccine
10.4 Industry Chain Structure of Infant and Child Multiple Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Infant and Child Multiple Vaccine Distributors
11.3 Infant and Child Multiple Vaccine Customer
12 WORLD FORECAST REVIEW FOR INFANT AND CHILD MULTIPLE VACCINE BY GEOGRAPHIC REGION
12.1 Global Infant and Child Multiple Vaccine Market Size Forecast by Region
12.1.1 Global Infant and Child Multiple Vaccine Forecast by Region (2027-2032)
12.1.2 Global Infant and Child Multiple Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Infant and Child Multiple Vaccine Forecast by Type (2027-2032)
12.7 Global Infant and Child Multiple Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.1.3 Sanofi Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.2.3 GSK Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Mitsubishi Tanabe Pharma
13.3.1 Mitsubishi Tanabe Pharma Company Information
13.3.2 Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.3.3 Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Mitsubishi Tanabe Pharma Main Business Overview
13.3.5 Mitsubishi Tanabe Pharma Latest Developments
13.4 KM Biologics
13.4.1 KM Biologics Company Information
13.4.2 KM Biologics Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.4.3 KM Biologics Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 KM Biologics Main Business Overview
13.4.5 KM Biologics Latest Developments
13.5 Wuhan Institute of Biological Products
13.5.1 Wuhan Institute of Biological Products Company Information
13.5.2 Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.5.3 Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Wuhan Institute of Biological Products Main Business Overview
13.5.5 Wuhan Institute of Biological Products Latest Developments
13.6 Walvax Biotechnology
13.6.1 Walvax Biotechnology Company Information
13.6.2 Walvax Biotechnology Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.6.3 Walvax Biotechnology Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Walvax Biotechnology Main Business Overview
13.6.5 Walvax Biotechnology Latest Developments
13.7 Chengdu Institute of Biological Products
13.7.1 Chengdu Institute of Biological Products Company Information
13.7.2 Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.7.3 Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Chengdu Institute of Biological Products Main Business Overview
13.7.5 Chengdu Institute of Biological Products Latest Developments
13.8 Minhai Biotechnology
13.8.1 Minhai Biotechnology Company Information
13.8.2 Minhai Biotechnology Infant and Child Multiple Vaccine Product Portfolios and Specifications
13.8.3 Minhai Biotechnology Infant and Child Multiple Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Minhai Biotechnology Main Business Overview
13.8.5 Minhai Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Infant and Child Multiple Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Infant and Child Multiple Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Pentavalent Vaccine
Table 4. Major Players of Quadruple Vaccine
Table 5. Major Players of Triple Vaccine
Table 6. Major Players of Others
Table 7. Global Infant and Child Multiple Vaccine Sales by Type (2021-2026) & (M Doses)
Table 8. Global Infant and Child Multiple Vaccine Sales Market Share by Type (2021-2026)
Table 9. Global Infant and Child Multiple Vaccine Revenue by Type (2021-2026) & ($ million)
Table 10. Global Infant and Child Multiple Vaccine Revenue Market Share by Type (2021-2026)
Table 11. Global Infant and Child Multiple Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 12. Global Infant and Child Multiple Vaccine Sale by Application (2021-2026) & (M Doses)
Table 13. Global Infant and Child Multiple Vaccine Sale Market Share by Application (2021-2026)
Table 14. Global Infant and Child Multiple Vaccine Revenue by Application (2021-2026) & ($ million)
Table 15. Global Infant and Child Multiple Vaccine Revenue Market Share by Application (2021-2026)
Table 16. Global Infant and Child Multiple Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 17. Global Infant and Child Multiple Vaccine Sales by Company (2021-2026) & (M Doses)
Table 18. Global Infant and Child Multiple Vaccine Sales Market Share by Company (2021-2026)
Table 19. Global Infant and Child Multiple Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Infant and Child Multiple Vaccine Revenue Market Share by Company (2021-2026)
Table 21. Global Infant and Child Multiple Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 22. Key Manufacturers Infant and Child Multiple Vaccine Producing Area Distribution and Sales Area
Table 23. Players Infant and Child Multiple Vaccine Products Offered
Table 24. Infant and Child Multiple Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Infant and Child Multiple Vaccine Sales by Geographic Region (2021-2026) & (M Doses)
Table 28. Global Infant and Child Multiple Vaccine Sales Market Share Geographic Region (2021-2026)
Table 29. Global Infant and Child Multiple Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Infant and Child Multiple Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Infant and Child Multiple Vaccine Sales by Country/Region (2021-2026) & (M Doses)
Table 32. Global Infant and Child Multiple Vaccine Sales Market Share by Country/Region (2021-2026)
Table 33. Global Infant and Child Multiple Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Infant and Child Multiple Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Infant and Child Multiple Vaccine Sales by Country (2021-2026) & (M Doses)
Table 36. Americas Infant and Child Multiple Vaccine Sales Market Share by Country (2021-2026)
Table 37. Americas Infant and Child Multiple Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Infant and Child Multiple Vaccine Sales by Type (2021-2026) & (M Doses)
Table 39. Americas Infant and Child Multiple Vaccine Sales by Application (2021-2026) & (M Doses)
Table 40. APAC Infant and Child Multiple Vaccine Sales by Region (2021-2026) & (M Doses)
Table 41. APAC Infant and Child Multiple Vaccine Sales Market Share by Region (2021-2026)
Table 42. APAC Infant and Child Multiple Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Infant and Child Multiple Vaccine Sales by Type (2021-2026) & (M Doses)
Table 44. APAC Infant and Child Multiple Vaccine Sales by Application (2021-2026) & (M Doses)
Table 45. Europe Infant and Child Multiple Vaccine Sales by Country (2021-2026) & (M Doses)
Table 46. Europe Infant and Child Multiple Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Infant and Child Multiple Vaccine Sales by Type (2021-2026) & (M Doses)
Table 48. Europe Infant and Child Multiple Vaccine Sales by Application (2021-2026) & (M Doses)
Table 49. Middle East & Africa Infant and Child Multiple Vaccine Sales by Country (2021-2026) & (M Doses)
Table 50. Middle East & Africa Infant and Child Multiple Vaccine Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Infant and Child Multiple Vaccine Sales by Type (2021-2026) & (M Doses)
Table 52. Middle East & Africa Infant and Child Multiple Vaccine Sales by Application (2021-2026) & (M Doses)
Table 53. Key Market Drivers & Growth Opportunities of Infant and Child Multiple Vaccine
Table 54. Key Market Challenges & Risks of Infant and Child Multiple Vaccine
Table 55. Key Industry Trends of Infant and Child Multiple Vaccine
Table 56. Infant and Child Multiple Vaccine Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Infant and Child Multiple Vaccine Distributors List
Table 59. Infant and Child Multiple Vaccine Customer List
Table 60. Global Infant and Child Multiple Vaccine Sales Forecast by Region (2027-2032) & (M Doses)
Table 61. Global Infant and Child Multiple Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Infant and Child Multiple Vaccine Sales Forecast by Country (2027-2032) & (M Doses)
Table 63. Americas Infant and Child Multiple Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Infant and Child Multiple Vaccine Sales Forecast by Region (2027-2032) & (M Doses)
Table 65. APAC Infant and Child Multiple Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Infant and Child Multiple Vaccine Sales Forecast by Country (2027-2032) & (M Doses)
Table 67. Europe Infant and Child Multiple Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Infant and Child Multiple Vaccine Sales Forecast by Country (2027-2032) & (M Doses)
Table 69. Middle East & Africa Infant and Child Multiple Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Infant and Child Multiple Vaccine Sales Forecast by Type (2027-2032) & (M Doses)
Table 71. Global Infant and Child Multiple Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Infant and Child Multiple Vaccine Sales Forecast by Application (2027-2032) & (M Doses)
Table 73. Global Infant and Child Multiple Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Sanofi Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 75. Sanofi Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 76. Sanofi Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 77. Sanofi Main Business
Table 78. Sanofi Latest Developments
Table 79. GSK Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. GSK Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 81. GSK Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 82. GSK Main Business
Table 83. GSK Latest Developments
Table 84. Mitsubishi Tanabe Pharma Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 86. Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 87. Mitsubishi Tanabe Pharma Main Business
Table 88. Mitsubishi Tanabe Pharma Latest Developments
Table 89. KM Biologics Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. KM Biologics Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 91. KM Biologics Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 92. KM Biologics Main Business
Table 93. KM Biologics Latest Developments
Table 94. Wuhan Institute of Biological Products Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 96. Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 97. Wuhan Institute of Biological Products Main Business
Table 98. Wuhan Institute of Biological Products Latest Developments
Table 99. Walvax Biotechnology Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Walvax Biotechnology Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 101. Walvax Biotechnology Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 102. Walvax Biotechnology Main Business
Table 103. Walvax Biotechnology Latest Developments
Table 104. Chengdu Institute of Biological Products Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 106. Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. Chengdu Institute of Biological Products Main Business
Table 108. Chengdu Institute of Biological Products Latest Developments
Table 109. Minhai Biotechnology Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Minhai Biotechnology Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 111. Minhai Biotechnology Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. Minhai Biotechnology Main Business
Table 113. Minhai Biotechnology Latest Developments
Table 1. Infant and Child Multiple Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Infant and Child Multiple Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Pentavalent Vaccine
Table 4. Major Players of Quadruple Vaccine
Table 5. Major Players of Triple Vaccine
Table 6. Major Players of Others
Table 7. Global Infant and Child Multiple Vaccine Sales by Type (2021-2026) & (M Doses)
Table 8. Global Infant and Child Multiple Vaccine Sales Market Share by Type (2021-2026)
Table 9. Global Infant and Child Multiple Vaccine Revenue by Type (2021-2026) & ($ million)
Table 10. Global Infant and Child Multiple Vaccine Revenue Market Share by Type (2021-2026)
Table 11. Global Infant and Child Multiple Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 12. Global Infant and Child Multiple Vaccine Sale by Application (2021-2026) & (M Doses)
Table 13. Global Infant and Child Multiple Vaccine Sale Market Share by Application (2021-2026)
Table 14. Global Infant and Child Multiple Vaccine Revenue by Application (2021-2026) & ($ million)
Table 15. Global Infant and Child Multiple Vaccine Revenue Market Share by Application (2021-2026)
Table 16. Global Infant and Child Multiple Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 17. Global Infant and Child Multiple Vaccine Sales by Company (2021-2026) & (M Doses)
Table 18. Global Infant and Child Multiple Vaccine Sales Market Share by Company (2021-2026)
Table 19. Global Infant and Child Multiple Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Infant and Child Multiple Vaccine Revenue Market Share by Company (2021-2026)
Table 21. Global Infant and Child Multiple Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 22. Key Manufacturers Infant and Child Multiple Vaccine Producing Area Distribution and Sales Area
Table 23. Players Infant and Child Multiple Vaccine Products Offered
Table 24. Infant and Child Multiple Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Infant and Child Multiple Vaccine Sales by Geographic Region (2021-2026) & (M Doses)
Table 28. Global Infant and Child Multiple Vaccine Sales Market Share Geographic Region (2021-2026)
Table 29. Global Infant and Child Multiple Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Infant and Child Multiple Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Infant and Child Multiple Vaccine Sales by Country/Region (2021-2026) & (M Doses)
Table 32. Global Infant and Child Multiple Vaccine Sales Market Share by Country/Region (2021-2026)
Table 33. Global Infant and Child Multiple Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Infant and Child Multiple Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Infant and Child Multiple Vaccine Sales by Country (2021-2026) & (M Doses)
Table 36. Americas Infant and Child Multiple Vaccine Sales Market Share by Country (2021-2026)
Table 37. Americas Infant and Child Multiple Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Infant and Child Multiple Vaccine Sales by Type (2021-2026) & (M Doses)
Table 39. Americas Infant and Child Multiple Vaccine Sales by Application (2021-2026) & (M Doses)
Table 40. APAC Infant and Child Multiple Vaccine Sales by Region (2021-2026) & (M Doses)
Table 41. APAC Infant and Child Multiple Vaccine Sales Market Share by Region (2021-2026)
Table 42. APAC Infant and Child Multiple Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Infant and Child Multiple Vaccine Sales by Type (2021-2026) & (M Doses)
Table 44. APAC Infant and Child Multiple Vaccine Sales by Application (2021-2026) & (M Doses)
Table 45. Europe Infant and Child Multiple Vaccine Sales by Country (2021-2026) & (M Doses)
Table 46. Europe Infant and Child Multiple Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Infant and Child Multiple Vaccine Sales by Type (2021-2026) & (M Doses)
Table 48. Europe Infant and Child Multiple Vaccine Sales by Application (2021-2026) & (M Doses)
Table 49. Middle East & Africa Infant and Child Multiple Vaccine Sales by Country (2021-2026) & (M Doses)
Table 50. Middle East & Africa Infant and Child Multiple Vaccine Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Infant and Child Multiple Vaccine Sales by Type (2021-2026) & (M Doses)
Table 52. Middle East & Africa Infant and Child Multiple Vaccine Sales by Application (2021-2026) & (M Doses)
Table 53. Key Market Drivers & Growth Opportunities of Infant and Child Multiple Vaccine
Table 54. Key Market Challenges & Risks of Infant and Child Multiple Vaccine
Table 55. Key Industry Trends of Infant and Child Multiple Vaccine
Table 56. Infant and Child Multiple Vaccine Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Infant and Child Multiple Vaccine Distributors List
Table 59. Infant and Child Multiple Vaccine Customer List
Table 60. Global Infant and Child Multiple Vaccine Sales Forecast by Region (2027-2032) & (M Doses)
Table 61. Global Infant and Child Multiple Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Infant and Child Multiple Vaccine Sales Forecast by Country (2027-2032) & (M Doses)
Table 63. Americas Infant and Child Multiple Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Infant and Child Multiple Vaccine Sales Forecast by Region (2027-2032) & (M Doses)
Table 65. APAC Infant and Child Multiple Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Infant and Child Multiple Vaccine Sales Forecast by Country (2027-2032) & (M Doses)
Table 67. Europe Infant and Child Multiple Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Infant and Child Multiple Vaccine Sales Forecast by Country (2027-2032) & (M Doses)
Table 69. Middle East & Africa Infant and Child Multiple Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Infant and Child Multiple Vaccine Sales Forecast by Type (2027-2032) & (M Doses)
Table 71. Global Infant and Child Multiple Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Infant and Child Multiple Vaccine Sales Forecast by Application (2027-2032) & (M Doses)
Table 73. Global Infant and Child Multiple Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Sanofi Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 75. Sanofi Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 76. Sanofi Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 77. Sanofi Main Business
Table 78. Sanofi Latest Developments
Table 79. GSK Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. GSK Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 81. GSK Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 82. GSK Main Business
Table 83. GSK Latest Developments
Table 84. Mitsubishi Tanabe Pharma Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 86. Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 87. Mitsubishi Tanabe Pharma Main Business
Table 88. Mitsubishi Tanabe Pharma Latest Developments
Table 89. KM Biologics Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. KM Biologics Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 91. KM Biologics Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 92. KM Biologics Main Business
Table 93. KM Biologics Latest Developments
Table 94. Wuhan Institute of Biological Products Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 96. Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 97. Wuhan Institute of Biological Products Main Business
Table 98. Wuhan Institute of Biological Products Latest Developments
Table 99. Walvax Biotechnology Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Walvax Biotechnology Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 101. Walvax Biotechnology Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 102. Walvax Biotechnology Main Business
Table 103. Walvax Biotechnology Latest Developments
Table 104. Chengdu Institute of Biological Products Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 106. Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. Chengdu Institute of Biological Products Main Business
Table 108. Chengdu Institute of Biological Products Latest Developments
Table 109. Minhai Biotechnology Basic Information, Infant and Child Multiple Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Minhai Biotechnology Infant and Child Multiple Vaccine Product Portfolios and Specifications
Table 111. Minhai Biotechnology Infant and Child Multiple Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. Minhai Biotechnology Main Business
Table 113. Minhai Biotechnology Latest Developments
LIST OF FIGURES
Figure 1. Picture of Infant and Child Multiple Vaccine
Figure 2. Infant and Child Multiple Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Infant and Child Multiple Vaccine Sales Growth Rate 2021-2032 (M Doses)
Figure 7. Global Infant and Child Multiple Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Infant and Child Multiple Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Infant and Child Multiple Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Infant and Child Multiple Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Pentavalent Vaccine
Figure 12. Product Picture of Quadruple Vaccine
Figure 13. Product Picture of Triple Vaccine
Figure 14. Product Picture of Others
Figure 15. Global Infant and Child Multiple Vaccine Sales Market Share by Type in 2026
Figure 16. Global Infant and Child Multiple Vaccine Revenue Market Share by Type (2021-2026)
Figure 17. Infant and Child Multiple Vaccine Consumed in 12 Months Below
Figure 18. Global Infant and Child Multiple Vaccine Market: 12 Months Below (2021-2026) & (M Doses)
Figure 19. Infant and Child Multiple Vaccine Consumed in 12 Months Above
Figure 20. Global Infant and Child Multiple Vaccine Market: 12 Months Above (2021-2026) & (M Doses)
Figure 21. Global Infant and Child Multiple Vaccine Sale Market Share by Application (2025)
Figure 22. Global Infant and Child Multiple Vaccine Revenue Market Share by Application in 2026
Figure 23. Infant and Child Multiple Vaccine Sales by Company in 2026 (M Doses)
Figure 24. Global Infant and Child Multiple Vaccine Sales Market Share by Company in 2026
Figure 25. Infant and Child Multiple Vaccine Revenue by Company in 2026 ($ millions)
Figure 26. Global Infant and Child Multiple Vaccine Revenue Market Share by Company in 2026
Figure 27. Global Infant and Child Multiple Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Infant and Child Multiple Vaccine Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Infant and Child Multiple Vaccine Sales 2021-2026 (M Doses)
Figure 30. Americas Infant and Child Multiple Vaccine Revenue 2021-2026 ($ millions)
Figure 31. APAC Infant and Child Multiple Vaccine Sales 2021-2026 (M Doses)
Figure 32. APAC Infant and Child Multiple Vaccine Revenue 2021-2026 ($ millions)
Figure 33. Europe Infant and Child Multiple Vaccine Sales 2021-2026 (M Doses)
Figure 34. Europe Infant and Child Multiple Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Infant and Child Multiple Vaccine Sales 2021-2026 (M Doses)
Figure 36. Middle East & Africa Infant and Child Multiple Vaccine Revenue 2021-2026 ($ millions)
Figure 37. Americas Infant and Child Multiple Vaccine Sales Market Share by Country in 2026
Figure 38. Americas Infant and Child Multiple Vaccine Revenue Market Share by Country (2021-2026)
Figure 39. Americas Infant and Child Multiple Vaccine Sales Market Share by Type (2021-2026)
Figure 40. Americas Infant and Child Multiple Vaccine Sales Market Share by Application (2021-2026)
Figure 41. United States Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Infant and Child Multiple Vaccine Sales Market Share by Region in 2026
Figure 46. APAC Infant and Child Multiple Vaccine Revenue Market Share by Region (2021-2026)
Figure 47. APAC Infant and Child Multiple Vaccine Sales Market Share by Type (2021-2026)
Figure 48. APAC Infant and Child Multiple Vaccine Sales Market Share by Application (2021-2026)
Figure 49. China Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. India Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Infant and Child Multiple Vaccine Sales Market Share by Country in 2026
Figure 57. Europe Infant and Child Multiple Vaccine Revenue Market Share by Country (2021-2026)
Figure 58. Europe Infant and Child Multiple Vaccine Sales Market Share by Type (2021-2026)
Figure 59. Europe Infant and Child Multiple Vaccine Sales Market Share by Application (2021-2026)
Figure 60. Germany Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 61. France Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Infant and Child Multiple Vaccine Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Infant and Child Multiple Vaccine Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Infant and Child Multiple Vaccine Sales Market Share by Application (2021-2026)
Figure 68. Egypt Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Infant and Child Multiple Vaccine in 2026
Figure 74. Manufacturing Process Analysis of Infant and Child Multiple Vaccine
Figure 75. Industry Chain Structure of Infant and Child Multiple Vaccine
Figure 76. Channels of Distribution
Figure 77. Global Infant and Child Multiple Vaccine Sales Market Forecast by Region (2027-2032)
Figure 78. Global Infant and Child Multiple Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Infant and Child Multiple Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Infant and Child Multiple Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Infant and Child Multiple Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Infant and Child Multiple Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Infant and Child Multiple Vaccine
Figure 2. Infant and Child Multiple Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Infant and Child Multiple Vaccine Sales Growth Rate 2021-2032 (M Doses)
Figure 7. Global Infant and Child Multiple Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Infant and Child Multiple Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Infant and Child Multiple Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Infant and Child Multiple Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Pentavalent Vaccine
Figure 12. Product Picture of Quadruple Vaccine
Figure 13. Product Picture of Triple Vaccine
Figure 14. Product Picture of Others
Figure 15. Global Infant and Child Multiple Vaccine Sales Market Share by Type in 2026
Figure 16. Global Infant and Child Multiple Vaccine Revenue Market Share by Type (2021-2026)
Figure 17. Infant and Child Multiple Vaccine Consumed in 12 Months Below
Figure 18. Global Infant and Child Multiple Vaccine Market: 12 Months Below (2021-2026) & (M Doses)
Figure 19. Infant and Child Multiple Vaccine Consumed in 12 Months Above
Figure 20. Global Infant and Child Multiple Vaccine Market: 12 Months Above (2021-2026) & (M Doses)
Figure 21. Global Infant and Child Multiple Vaccine Sale Market Share by Application (2025)
Figure 22. Global Infant and Child Multiple Vaccine Revenue Market Share by Application in 2026
Figure 23. Infant and Child Multiple Vaccine Sales by Company in 2026 (M Doses)
Figure 24. Global Infant and Child Multiple Vaccine Sales Market Share by Company in 2026
Figure 25. Infant and Child Multiple Vaccine Revenue by Company in 2026 ($ millions)
Figure 26. Global Infant and Child Multiple Vaccine Revenue Market Share by Company in 2026
Figure 27. Global Infant and Child Multiple Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Infant and Child Multiple Vaccine Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Infant and Child Multiple Vaccine Sales 2021-2026 (M Doses)
Figure 30. Americas Infant and Child Multiple Vaccine Revenue 2021-2026 ($ millions)
Figure 31. APAC Infant and Child Multiple Vaccine Sales 2021-2026 (M Doses)
Figure 32. APAC Infant and Child Multiple Vaccine Revenue 2021-2026 ($ millions)
Figure 33. Europe Infant and Child Multiple Vaccine Sales 2021-2026 (M Doses)
Figure 34. Europe Infant and Child Multiple Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Infant and Child Multiple Vaccine Sales 2021-2026 (M Doses)
Figure 36. Middle East & Africa Infant and Child Multiple Vaccine Revenue 2021-2026 ($ millions)
Figure 37. Americas Infant and Child Multiple Vaccine Sales Market Share by Country in 2026
Figure 38. Americas Infant and Child Multiple Vaccine Revenue Market Share by Country (2021-2026)
Figure 39. Americas Infant and Child Multiple Vaccine Sales Market Share by Type (2021-2026)
Figure 40. Americas Infant and Child Multiple Vaccine Sales Market Share by Application (2021-2026)
Figure 41. United States Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Infant and Child Multiple Vaccine Sales Market Share by Region in 2026
Figure 46. APAC Infant and Child Multiple Vaccine Revenue Market Share by Region (2021-2026)
Figure 47. APAC Infant and Child Multiple Vaccine Sales Market Share by Type (2021-2026)
Figure 48. APAC Infant and Child Multiple Vaccine Sales Market Share by Application (2021-2026)
Figure 49. China Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. India Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Infant and Child Multiple Vaccine Sales Market Share by Country in 2026
Figure 57. Europe Infant and Child Multiple Vaccine Revenue Market Share by Country (2021-2026)
Figure 58. Europe Infant and Child Multiple Vaccine Sales Market Share by Type (2021-2026)
Figure 59. Europe Infant and Child Multiple Vaccine Sales Market Share by Application (2021-2026)
Figure 60. Germany Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 61. France Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Infant and Child Multiple Vaccine Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Infant and Child Multiple Vaccine Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Infant and Child Multiple Vaccine Sales Market Share by Application (2021-2026)
Figure 68. Egypt Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Infant and Child Multiple Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Infant and Child Multiple Vaccine in 2026
Figure 74. Manufacturing Process Analysis of Infant and Child Multiple Vaccine
Figure 75. Industry Chain Structure of Infant and Child Multiple Vaccine
Figure 76. Channels of Distribution
Figure 77. Global Infant and Child Multiple Vaccine Sales Market Forecast by Region (2027-2032)
Figure 78. Global Infant and Child Multiple Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Infant and Child Multiple Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Infant and Child Multiple Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Infant and Child Multiple Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Infant and Child Multiple Vaccine Revenue Market Share Forecast by Application (2027-2032)
